FDA Approves VELCADE (Bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma
- Topics:
- Pharmeceuticals
- Source:
- Millennium Pharmaceuticals
FREE Registration is required
Overview: This article discusses the Millennium Pharmaceuticals, Inc. approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit such as an improvement in survival. VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma - a cancer of the blood.
(Is this item miscategorized? Does it need more tags? Let us know.)
Format: HTML | Pages: 4
People who downloaded this item also downloaded
 |
Strengths, Weaknesses, Opportunities and Threats (SWOT) |
 |
Apple Computer Case Study: Hampton City Schools |
